Stocks in news: RIL, Jio, Trent, Suzlon Energy, IndiGo, Vedanta Power and RVNL

Indian equities extended their recovery on Thursday, with the Nifty closing firmly above the 22,900 mark as buying momentum broadened beyond banking stocks. The Nifty 50 advanced 238 points, or 1.05%, to settle at 22,937.

From a technical perspective, the index closed above its 20-day simple moving average (SMA) and crossed the important 22,800 level. This level is expected to act as immediate support, while a sustained move above 22,900 could extend the recovery towards 23,000-23,150, according to Hariselvan Radhakrishnan, founder and CEO of HST Wealth.

Against this backdrop, several stocks, including Reliance Industries, Jio Platforms, Trent, Suzlon Energy, IndiGo, Vedanta Power, Sagility and Rail Vikas Nigam, are likely to remain in focus on Friday, October 30. Investors will track September-quarter earnings, fundraising plans, credit rating updates, regulatory developments and new business wins.


ALSO READ: RIL Q2 Results Preview: Profit outlook brightens as O2C business set to drive growth

Trent

Tata Group retail company Trent reported a 25.3% year-on-year (YoY) increase in consolidated profit to Rs 468.09 crore in the September quarter of FY27 (Q2FY27), compared with Rs 373.42 crore in the corresponding quarter of the previous financial year (Q2FY26).

Motilal Oswal

Motilal Oswal reported a 29% YoY increase in operating profit after tax (PAT) to Rs 718 crore for the September quarter, compared with Rs 554 crore a year earlier. The growth was driven by strong performance in its asset management business.

Suzlon Energy

Suzlon Energy reported a 69% YoY decline in consolidated net profit to Rs 394 crore for the September quarter, compared with Rs 1,279 crore in the corresponding period last year. However, revenue increased 26% on the back of record wind turbine deliveries.

The sharp decline in reported profit was largely attributable to a high base in the year-ago quarter, when the renewable energy company recognised a one-time deferred tax asset benefit of Rs 891 crore.

IndiGo

Budget airline IndiGo reported a narrowing of its consolidated loss to Rs 1,879 crore in the second quarter of FY27, compared with Rs 2,582 crore in the year-ago quarter. However, the loss widened from Rs 237 crore reported in the preceding June quarter.

ALSO READ: Ahead of Market: 10 things that will decide stock market action on Friday

Sagility

Promoter Sagility B.V. is likely to sell a 12% stake in healthcare-focused IT-enabled services provider Sagility through a block deal, according to reports.

The offer size is pegged at Rs 2,377 crore, with the floor price set at Rs 42.45 per share, implying a discount of up to 4.9% to the stock's previous closing price. The promoter will be subject to a 365-day lock-up on its residual stake.

According to the September-quarter shareholding data, Sagility B.V. held 2,38,51,29,151 shares, representing a 50.95% stake in the company. If the proposed transaction goes through, the promoter's shareholding will decline.

Vedanta Power

Vedanta Power reported a turnaround in its September-quarter earnings for FY27, posting a profit after tax (PAT) of Rs 83 crore against a net loss of Rs 1,688 crore in the year-ago quarter. The company had reported a net loss of Rs 423 crore in the June quarter of FY27.

Revenue from operations rose 38% YoY to Rs 2,908 crore in the second quarter of FY27, compared with Rs 2,104 crore in the corresponding quarter of the previous financial year.

ALSO READ: Trent Q2 Results: Cons profit jumps 25% YoY to Rs 468 crore; revenue climbs 22%

Godrej Consumer Products

Godrej Consumer Products reported a 13.8% YoY increase in consolidated profit after tax (PAT) to Rs 522.92 crore in Q2FY27, compared with Rs 459.34 crore in the corresponding quarter of the previous financial year.

Revenue from operations rose 19% YoY to Rs 4,413.09 crore during the quarter, against Rs 3,708.19 crore in Q2FY26. Consolidated EBITDA grew 12% YoY to Rs 820 crore, according to the company's exchange filing.

Mankind Pharma

CRISIL Ratings has reaffirmed the credit ratings on two non-convertible debenture (NCD) instruments issued by Mankind Pharma, while withdrawing the ratings on another NCD instrument and its commercial paper, according to a company disclosure dated October 29, 2026.

The Rs 400 crore and Rs 2,100 crore NCD instruments retain their CRISIL AA+/Stable ratings. The rating on the Rs 2,500 crore NCD instrument has been withdrawn, as has the CRISIL A1+ rating on the company's Rs 1,500 crore commercial paper.

Rail Vikas Nigam

Rail Vikas Nigam Ltd (RVNL) has received a letter of award (LoA) from the Ministry of External Affairs for preparing a detailed project report (DPR) for setting up a Professional and Technical Education Centre (PTEC) in Seychelles.

ALSO READ: Market Trading Guide: Eternal among 2 stocks to buy for Friday for healthy returns

Q2 results today

Reliance Industries, Jio Platforms, Sun Pharmaceutical Industries, Bharat Electronics, Indian Oil Corporation, Varun Beverages, Bank of Baroda, GAIL India, GE Vernova T&D India, Lodha Developers, Aditya Birla Capital, Max Healthcare Institute, NTPC Green Energy, Phoenix Mills, Dixon Technologies, General Insurance Corporation of India, PB Fintech, Ajanta Pharma, Navin Fluorine International, Narayana Hrudayalaya, Syrma SGS Technology, Delhivery, LIC Housing Finance, New India Assurance Company, Gabriel India and Sun TV Network.

Disclosure: This article has been written by Kumar Gaurav, who is not a Sebi-registered Research Analyst or an Investment Adviser. Gaurav and their ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective Sebi-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here